Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Beside...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maki Komiyama, Koji Hasegawa
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/7acc58e8d34841e5b13c850b25605391
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7acc58e8d34841e5b13c850b25605391
record_format	dspace
spelling	oai:doaj.org-article:7acc58e8d34841e5b13c850b256053912021-12-04T16:03:22ZAnticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness10.15420/ecr.2020.241758-37641758-3756https://doaj.org/article/7acc58e8d34841e5b13c850b256053912020-08-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.24https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom. Multiple retrospective studies have strongly suggested that anticoagulant therapy improves the prognosis of people with COVID-19. However, validation of the safety and effectiveness of anticoagulant therapy for COVID-19 and greater awareness of this clinical therapeutic option are urgently needed.Maki KomiyamaKoji HasegawaRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 15, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Maki Komiyama Koji Hasegawa Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
description	Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom. Multiple retrospective studies have strongly suggested that anticoagulant therapy improves the prognosis of people with COVID-19. However, validation of the safety and effectiveness of anticoagulant therapy for COVID-19 and greater awareness of this clinical therapeutic option are urgently needed.
format	article
author	Maki Komiyama Koji Hasegawa
author_facet	Maki Komiyama Koji Hasegawa
author_sort	Maki Komiyama
title	Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
title_short	Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
title_full	Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
title_fullStr	Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
title_full_unstemmed	Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
title_sort	anticoagulant therapy for patients with coronavirus disease 2019: urgent need for enhanced awareness
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/7acc58e8d34841e5b13c850b25605391
work_keys_str_mv	AT makikomiyama anticoagulanttherapyforpatientswithcoronavirusdisease2019urgentneedforenhancedawareness AT kojihasegawa anticoagulanttherapyforpatientswithcoronavirusdisease2019urgentneedforenhancedawareness
_version_	1718372744501919744

Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness

Ejemplares similares